Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure

Edoardo Gronda, Emilio Vanoli

Research output: Contribution to journalArticlepeer-review


Baroreflex activation therapy (BAT) produces a central inhibition of cardiac sympathetic outflow and, concomitantly, an increased cardiac vagal activity via a physiological reflex pathway. In a pilot study in 11 patients with NYHA class III heart failure (HF), BAT produced a persistent significant reduction of muscle sympathetic nerve activity over a 21-month follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA functional class III HF, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p = 0.02). This was associated with a trend toward few in hospital days for HF. BAT might become a powerful tool to manipulate autonomic alterations of HF at their origin and thus profoundly affect advanced HF patient prognosis.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCurrent Alzheimer Research
Publication statusAccepted/In press - Nov 16 2016


  • Autonomic nervous system
  • Baroreflex activation
  • Heart failure
  • Non-pharmacologic therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine


Dive into the research topics of 'Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure'. Together they form a unique fingerprint.

Cite this